Abstract:Background and Purpose Endomorphins (EMs) have shown great promise as pharmaceutics for the treatment of pain. We have previously confirmed that novel EM analogs CEMR‐1 and CEMR‐2 behaved as potent μ‐opioid receptor agonists and displayed potent antinociceptive activities at the supraspinal and peripheral levels. Herein, the present study was undertaken to evaluate the antinociceptive properties of CEMR‐1 and CEMR‐2 following intrathecal (i.t.) administration. Furthermore, their antinociceptive tolerance and opioid‐like side effects were also determined. Experimental Approach The spinal antinociceptive effects of CEMR‐1 and CEMR‐2 were determined in a series of pain models, including acute radiant heat paw withdrawal test, spared nerve injury (SNI)‐induced neuropathic pain, complete Freund’s adjuvant (CFA)‐induced inflammatory pain, visceral pain and formalin pain. Antinociceptive tolerance was evaluated in radiant heat paw withdrawal test. Key Results Spinal administration of CEMR‐1 and CEMR‐2 produced potent and prolonged antinociceptive effects in acute pain. CEMR‐1 and CEMR‐2 may produce their antinociception through distinct μ‐opioid receptor subtypes. These two analogs also exhibited significant analgesic activities in neuropathic, inflammatory, visceral and formalin pain at the spinal level. It is noteworthy that CEMR‐1 showed non‐tolerance‐forming analgesic properties, and CEMR‐2 exhibited substantially reduced antinociceptive tolerance. Furthermore, both analogs displayed no or reduced side effects on CPP response, physical dependence, locomotor activity and gastrointestinal transit. Conclusions and Implications The present investigation demonstrated that CEMR‐1 and CEMR‐2 displayed potent and long‐lasting antinociception with a favorable side effect profile at the spinal level. Therefore, CEMR‐1 and CEMR‐2 might serve as promising analgesic compounds with minimized opioid‐like side effects.

Structure–activity Relationships of Novel Endomorphin-2 Analogues with N–O Turns Induced by Α-Aminoxy Acids

Synthesis and Biological Evaluations of Novel Endomorphin Analogues Containing Α-Hydroxy-β-phenylalanine (AHPBA) Displaying Mixed Μ/δ Opioid Receptor Agonist and Δ Opioid Receptor Antagonist Activities.

Endomorphins: Promising Endogenous Opioid Peptides for the Development of Novel Analgesics

Conformational Analysis of Endomorphin-2 Analogs with Phenylalanine Mimics by NMR and Molecular Modeling.

Novel Cyclic Endomorphin Analogues with Multiple Modifications and Oligoarginine Vector Exhibit Potent Antinociception with Reduced Opioid-like Side Effects

Structural Basis for Bifunctional Peptide Recognition at Human Δ-Opioid Receptor

Structure activity relationship studies of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3'-carboxamido)morphinan (NAQ) analogues as potent opioid receptor ligands: preliminary results on the role of electronic characteristics for affinity and function.

Design, syntheses, and pharmacological characterization of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3'-carboxamido)morphinan analogues as opioid receptor ligands.

Design, Syntheses, and Pharmacological Characterization of 17-Cyclopropylmethyl-3,14 Beta-Dihydroxy-4,5 Alpha-Epoxy-6 Alpha-(Isoquinoline-3 '-Carboxamido)morphinan Analogues As Opioid Receptor Ligands

Structure selectivity relationship studies of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-[(4'-pyridyl)carboxamido]morphinan derivatives toward the development of the mu opioid receptor antagonists.

Design, Synthesis, and Biological Evaluation of the Third Generation 17-Cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-[(4'-pyridyl)carboxamido]morphinan (NAP) Derivatives As Μ/κ Opioid Receptor Dual Selective Ligands.

Structure activity relationship studies of 6α- and 6β-indolylacetamidonaltrexamine derivatives as bitopic mu opioid receptor modulators and elaboration of the 'message-address concept' to comprehend their functional conversion.

Application of Bivalent Bioisostere Concept on Design and Discovery of Potent Opioid Receptor Modulators

Contribution of the μ opioid receptor and enkephalin to the antinociceptive actions of endomorphin-1 analogs with unnatural amino acid modifications in the spinal cord

Novel endomorphin analogs CEMR‐1 and CEMR‐2 produce potent and long‐lasting antinociception with a favorable side effect profile at the spinal level

Novel chimeric peptides based on endomorphins and ghrelin receptor antagonist produced supraspinal antinociceptive effects with reduced acute tolerance in mice

Design, Synthesis, and Biological Evaluation of 17-Cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-[(4'-pyridyl)carboxamido]morphinan Derivatives As Peripheral Selective Μ Opioid Receptor Agents.

Binding Mode Analyses of NAP Derivatives As Mu Opioid Receptor Selective Ligands Through Docking Studies and Molecular Dynamics Simulation

Design, synthesis, and biological evaluation of 6α- and 6β-N-heterocyclic substituted naltrexamine derivatives as μ opioid receptor selective Antagonists

Exploring Naltrexamine Derivatives Featuring Azaindole Moiety Via Nitrogen-Walk Approach to Investigate Their in Vitro Pharmacological Profiles at the Mu Opioid Receptor

Synthesis and Evaluation of Κ-Opioid Receptor Agonistic Activity and Antinociceptive Effect of Novel Morphine Analogues, 7Α-Phenyl-6α,14α-endo-etheno-tetrahydrothebaine with Substituted O-, M- and P-Amino Group